Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Income towards Parent Company: 2023-2024

Historic Income towards Parent Company for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$14.6 million.

  • Contineum Therapeutics' Income towards Parent Company fell 87.48% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 285.94%. This contributed to the annual value of -$42.3 million for FY2024, which is 285.99% down from last year.
  • Per Contineum Therapeutics' latest filing, its Income towards Parent Company stood at -$14.6 million for Q4 2024, which was down 41.86% from -$10.3 million recorded in Q3 2024.
  • Contineum Therapeutics' 5-year Income towards Parent Company high stood at $41.6 million for Q2 2023, and its period low was -$14.6 million during Q4 2024.
  • Over the past 2 years, Contineum Therapeutics' median Income towards Parent Company value was -$8.1 million (recorded in 2023), while the average stood at -$2.4 million.
  • Data for Contineum Therapeutics' Income towards Parent Company shows a maximum YoY slumped of 121.67% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Contineum Therapeutics' Income towards Parent Company stood at -$7.8 million in 2023, then tumbled by 87.48% to -$14.6 million in 2024.
  • Its last three reported values are -$14.6 million in Q4 2024, -$10.3 million for Q3 2024, and -$9.0 million during Q2 2024.